PATENT CLAIM ANALYSIS

Application Number: 16129896
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "649000"]

Abstract:
Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of Δβ and α-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.

Claim (Index 7):
The pharmaceutical composition according to  claim 5 , wherein the cysteine-containing tripeptides glycine-L-cysteine-L-arginine tripeptide (GCR), L-proline-L-cysteine-L-arginine tripeptide (PCR), L-lysine-L-cysteine-L-proline tripeptide (KCP), or L-glutathione (GSH).

Metadata:
- Claim Count in Document: 29.0
- Percentile: 97.0
- Lexical Diversity: 1.68182
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14350912', '13958725', '15688484', '14962664', '13636877']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6836896454797554
- 35 USC 102 Novelty (BERT): 0.5178899958076032
- Combined Prediction Score: 0.6671096805125403
- Mean Citation Score: 191.33626
- Max Citation Score: 219.21663
- Similarity Product: 125.8348798453492

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test